Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs
Open Access
- 14 September 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (9) , e0136207
Abstract
Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or refractory to bortezomib and lenalidomide, carries a poor prognosis. The healthcare costs of DRMM have not previously been reported. We analyzed detailed medical resource utilization (MRU) costs, drug costs and outcomes for 39 UK patients receiving standard DRMM therapy. Median OS in this cohort was 5.6 months. The mean cost of DRMM treatment plus MRU until death was £23,472 [range: £1,411–£90,262], split between drug costs £11,191 and other resource use costs £12,281. The cost per assumed quality-adjusted life year (QALY) during DRMM was £66,983. These data provide a standard of care comparison when evaluating the cost-effectiveness of new drugs in DRMM.Keywords
This publication has 13 references indexed in Scilit:
- Cancer Drugs in the United States: Justum Pretium—The Just PriceJournal of Clinical Oncology, 2013
- Management of Double-Refractory Multiple MyelomaCurrent Hematologic Malignancy Reports, 2013
- Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population‐based analysisBritish Journal of Haematology, 2013
- Total cost comparison in relapsed/refractory multiple myelomaJournal of Medical Economics, 2013
- Efficient Allocation of Novel Agents in Multiple Myeloma: A Work in ProgressThe Oncologist, 2013
- Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims DataThe Oncologist, 2013
- Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agentsJournal of Clinical Pharmacy and Therapeutics, 2012
- Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and WalesThe European Journal of Health Economics, 2012
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyLeukemia, 2011
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1Blood, 2011